New hope for Crohn's patients: study tests guselkumab after ustekinumab fails

NCT ID NCT07310095

Recruiting now Disease control Sponsor: Xian-Janssen Pharmaceutical Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests whether guselkumab can help people with Crohn's disease whose current treatment (ustekinumab) has stopped working. Crohn's disease causes severe gut inflammation. About 78 Chinese adults with active Crohn's will receive guselkumab and be followed for 48 weeks to see if their symptoms improve. The goal is to reduce inflammation and achieve remission without needing lifelong medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE

Contacts and locations

Locations

Ruijin Hospital
RECRUITING

Shanghai, 200031, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, 310018, China
The First Affiliated Hospital Sun Yat sen University
RECRUITING

Guangzhou, 510060, China
The First Affiliated Hospital of Anhui Medical University
RECRUITING

Hefei, 230022, China
The Sixth Affiliated Hospital Sun Yat sen University
RECRUITING

Guangzhou, 510655, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.